A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413
This study is recruiting at 23 US sites in 15 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- NSCLC Adenocarcinoma
- Gastroesophageal Cancer (GC)
- Gastric Adenocarcinoma
- Adenocarcinoma of Esophagus
- Squamous Cell Car. - Esophagus
- Urothelial Carcinoma (UC)
- Bladder Cancer
- Mesothelioma
- Pleural Mesothelioma
- Peritoneal Mesothelioma
- Non-Small Cell Lung Cancer NSCLC
- Pancreatic Cancer
- Biliary Tract Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- IDEAYA Biosciences
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- City of Hope Cancer Center-Phoenix · Goodyear, AZ
- Mayo Clinic Arizona · Phoenix, AZ
California · 2
- City of Hope Cancer Center-Duarte · Duarte, CA
- Providence Medical Foundation · Santa Rosa, CA
District of Columbia · 1
- Johns Hopkins Sibley Memorial Hospital · Washington D.C., DC
Florida · 4
- BRCR Global-Coral Springs · Coral Springs, FL
- Mayo Clinic Florida · Jacksonville, FL
- Sarah Cannon Research Institute at Florida Cancer Specialists · Orlando, FL
- Moffitt Cancer Center · Tampa, FL
Illinois · 1
- City of Hope Cancer Center-Chicago · Zion, IL
Minnesota · 1
- Mayo Clinic Rochester · Rochester, MN
Nebraska · 1
- Nebraska Cancer Specialists · Omaha, NE
New Jersey · 1
- START Astera, LLC · East Brunswick, NJ
New York · 1
- Columbia University Irving Medical Center · New York, NY
Pennsylvania · 1
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University · Philadelphia, PA
Tennessee · 1
- Sarah Cannon Research Institute · Nashville, TN
Texas · 4
- START Dallas Fort Worth · Fort Worth, TX
- MD Anderson · Houston, TX
- NEXT Oncology Houston · Houston, TX
- NEXT Oncology Dallas · Irving, TX
Utah · 1
- START Mountain Region, LLC · West Valley City, UT
Virginia · 1
- NEXT Oncology Virginia · Fairfax, VA
Washington · 1
- Swedish Cancer Institute · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.